Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (801-810 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|May 24, 2014
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studiesAntoine Deslandes
Mabs|May 16, 2014
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19Dániel Szili, Marcell Cserhalmi, Zsuzsanna Bankó, et al.
Mabs|March 17, 2015
Fab-based bispecific antibody formats with robust biophysical properties and biological activityXiufeng Wu, Arlene J Sereno, Flora Huang, et al.
Mabs|March 3, 2015
Insights into the molecular basis of a bispecific antibody's target selectivityYariv Mazor, Anna Hansen, Chunning Yang, et al.
Mabs|March 12, 2015
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicityValerie R Wiersma, Marco de Bruyn, Ce Shi, et al.
Mabs|March 12, 2015
Aggregation risk prediction for antibodies and its application to biotherapeutic developmentOlga Obrezanova, Andreas Arnell, Ramón Gómez de la Cuesta, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Mabs|April 16, 2015
Production of α2,6-sialylated IgG1 in CHO cellsCéline Raymond, Anna Robotham, Maureen Spearman, et al.
Mabs|October 13, 2025
Correction
Mabs|July 24, 2012
Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypesJanardan P Pandey
Pageof 184

Showing results (801-810 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|May 24, 2014
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studiesAntoine Deslandes
Mabs|May 16, 2014
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19Dániel Szili, Marcell Cserhalmi, Zsuzsanna Bankó, et al.
Mabs|March 17, 2015
Fab-based bispecific antibody formats with robust biophysical properties and biological activityXiufeng Wu, Arlene J Sereno, Flora Huang, et al.
Mabs|March 3, 2015
Insights into the molecular basis of a bispecific antibody's target selectivityYariv Mazor, Anna Hansen, Chunning Yang, et al.
Mabs|March 12, 2015
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicityValerie R Wiersma, Marco de Bruyn, Ce Shi, et al.
Mabs|March 12, 2015
Aggregation risk prediction for antibodies and its application to biotherapeutic developmentOlga Obrezanova, Andreas Arnell, Ramón Gómez de la Cuesta, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Mabs|April 16, 2015
Production of α2,6-sialylated IgG1 in CHO cellsCéline Raymond, Anna Robotham, Maureen Spearman, et al.
Mabs|October 13, 2025
Correction
Mabs|July 24, 2012
Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypesJanardan P Pandey
Pageof 184